Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
INN-12
- Development stage
- Preclinical
- Lead developer
- Innox Pharma
- Modality
- Small Molecules
01
Overview
INN-12 is a small molecule inhibitor of Rho-associated protein kinase 2 (ROCK-2) developed by Innox Pharma. ROCK-2 is a serine/threonine kinase that plays a critical role in regulating the actin cytoskeleton, cell polarity, and inflammatory gene expression. By selectively inhibiting ROCK-2, INN-12 aims to modulate pathways involved in fibrosis and inflammation. While the specific therapeutic indication for INN-12 has not been publicly disclosed, the drug is in an advanced stage of development, with documentation indicating that a New Drug Application (NDA) submission has been initiated or mentioned in regulatory contexts.
02
Targets
ROCK2 (Rho-associated coiled-coil containing protein kinase 2)
Beyond the preview
Go deeper on INN-12.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on INN-12.